Photo from Paolo Tarantino/X
Jul 14, 2024, 02:45
Paolo Tarantino: ASCO Post features ATEMPT’s 5 year update
Paolo Tarantino shared on X:
“Thanks to the ASCO Post for featuring our JCO publication of the ATEMPT 5-year update!
With <1% risk of distant recurrence at 5 years and improved quality of life over chemo, adjuvant T-DM1 should be considered as a valid alternative to TH for stage I HER2+ BC.”
Source: Paolo Tarantino/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 22, 2024, 04:52
Dec 22, 2024, 04:49
Dec 21, 2024, 22:40
Dec 21, 2024, 22:37